Survival benefits with EPIC in addition to HIPEC for low grade appendiceal neoplasms with pseudomyxoma peritonei: a propensity score matched study.

Raymond HaylerKathleen LockhartShoma BaratErnest ChengJasmine MuiRaphael ShamavonianNima AhmadiNayef AlzahraniWinston LiauwDavid Morris

Published in: Pleura and peritoneum (2023)

In LAMN with PMP, the addition of EPIC to HIPEC with CRS improves overall survival in propensity score matched cases but results in prolonged hospitalisation. The use of EPIC should still be considered in selected patients.

Keyphrases

low grade
high grade
end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
prognostic factors
patient reported outcomes